This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cerevel Therapeutics Holdings Toekomstige groei
Future criteriumcontroles 0/6
Cerevel Therapeutics Holdings is forecast to grow earnings and revenue by 17% and 69.6% per annum respectively while EPS is expected to grow by 22.4% per annum.
Belangrijke informatie
17.0%
Groei van de winst
22.4%
Groei van de winst per aandeel
| Biotechs winstgroei | 28.8% |
| Inkomstengroei | 69.6% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 02 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 65 | -541 | N/A | -499 | 1 |
| 12/31/2025 | N/A | -548 | N/A | -535 | 1 |
| 12/31/2024 | N/A | -441 | N/A | -386 | 2 |
| 3/31/2024 | N/A | -460 | -371 | -367 | N/A |
| 12/31/2023 | N/A | -433 | -346 | -342 | N/A |
| 9/30/2023 | N/A | -393 | -336 | -332 | N/A |
| 6/30/2023 | N/A | -397 | -343 | -340 | N/A |
| 3/31/2023 | N/A | -388 | -323 | -320 | N/A |
| 12/31/2022 | N/A | -352 | -297 | -293 | N/A |
| 9/30/2022 | N/A | -318 | -263 | -258 | N/A |
| 6/30/2022 | N/A | -280 | -227 | -222 | N/A |
| 3/31/2022 | N/A | -243 | -218 | -210 | N/A |
| 12/31/2021 | N/A | -225 | -189 | -179 | N/A |
| 9/30/2021 | N/A | -196 | -184 | -168 | N/A |
| 6/30/2021 | N/A | -173 | -167 | -144 | N/A |
| 3/31/2021 | N/A | -146 | -146 | -125 | N/A |
| 12/31/2020 | N/A | -148 | -137 | -118 | N/A |
| 9/30/2020 | N/A | -175 | -124 | -112 | N/A |
| 6/30/2020 | N/A | -172 | -116 | -111 | N/A |
| 3/31/2020 | N/A | -151 | -97 | -94 | N/A |
| 12/31/2019 | N/A | -128 | -72 | -71 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: CERE is forecast to remain unprofitable over the next 3 years.
Winst versus markt: CERE is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: CERE is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: CERE is forecast to have no revenue next year.
Hoge groei-inkomsten: CERE is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if CERE's Return on Equity is forecast to be high in 3 years time